# Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisal

**Authors:** F. H. van Bruggen, H. J. Luijendijk

PMC · DOI: 10.3389/fcvm.2025.1564432 · Frontiers in Cardiovascular Medicine · 2025-06-19

## Full-text entities

- **Diseases:** Type 2 MI (MESH:D003924)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12221899/full.md

## References

33 references — full list in the complete paper: https://tomesphere.com/paper/PMC12221899/full.md

---
Source: https://tomesphere.com/paper/PMC12221899